Form 4 Filing for Thomas K Equels

This SEC filing details a transaction made by Thomas K Equels, CEO & President of AIM ImmunoTech Inc. On September 16, 2026, Equels acquired 11,000 shares of Common Stock at a price of $0.21 per share. Following this transaction, Equels directly owns 102,822 shares of the company's stock. The filing is made on Form 4, with the signature date of September 17, 2026.